[go: up one dir, main page]

ATE386538T1 - Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden - Google Patents

Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden

Info

Publication number
ATE386538T1
ATE386538T1 AT02710762T AT02710762T ATE386538T1 AT E386538 T1 ATE386538 T1 AT E386538T1 AT 02710762 T AT02710762 T AT 02710762T AT 02710762 T AT02710762 T AT 02710762T AT E386538 T1 ATE386538 T1 AT E386538T1
Authority
AT
Austria
Prior art keywords
factor
polypeptides
factor viii
factor vii
combined use
Prior art date
Application number
AT02710762T
Other languages
English (en)
Inventor
Jens Knudsen
Ulla Hedner
Rasmus Roejkjfr
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of ATE386538T1 publication Critical patent/ATE386538T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02710762T 2001-02-05 2002-02-05 Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden ATE386538T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100186 2001-02-05

Publications (1)

Publication Number Publication Date
ATE386538T1 true ATE386538T1 (de) 2008-03-15

Family

ID=8160159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02710762T ATE386538T1 (de) 2001-02-05 2002-02-05 Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden

Country Status (16)

Country Link
US (5) US20030199444A1 (de)
EP (2) EP1359935A1 (de)
JP (2) JP2004517950A (de)
KR (2) KR20030078901A (de)
CN (2) CN1499981A (de)
AT (1) ATE386538T1 (de)
AU (1) AU2002229510A1 (de)
BR (2) BR0207007A (de)
CA (2) CA2436807A1 (de)
DE (1) DE60225118T2 (de)
ES (1) ES2301624T3 (de)
HU (2) HUP0303130A2 (de)
IL (2) IL156842A0 (de)
PL (2) PL365293A1 (de)
RU (2) RU2311923C2 (de)
WO (2) WO2002062376A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CA2406583A1 (en) * 2000-05-10 2001-11-15 Novo Nordisk A/S Pharmaceutical composition comprising a factor viia and a factor xiii
BR0113854A (pt) 2000-09-13 2004-07-06 Novo Nordisk As Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
EP1432794B1 (de) * 2001-09-27 2011-11-09 Novo Nordisk Health Care AG Menschliche gerinnungsfaktor-vii-polypeptide
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
EP1446148A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit einem faktor-vii-polypeptid und epsilon-aminocapronsäure
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP2392655A3 (de) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Gerinnungsfaktor VII Polypeptide
CN103251647A (zh) * 2004-05-27 2013-08-21 巴克斯特国际公司 应用硫酸多糖治疗出血障碍的方法
ES2331653T3 (es) * 2004-06-21 2010-01-12 Novo Nordisk Health Care Ag Factor viia o equivalentes de factor viia para prevenir o atenuar el crecimiento hemorragico, y/o la generacion de edema despues de una hemorragia intracerebral (ich).
EP1855712A2 (de) * 2005-02-28 2007-11-21 Novo Nordisk Health Care AG Fxiii-varianten mit verbesserten eigenschaften
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP2009543841A (ja) * 2006-07-17 2009-12-10 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
EP1988101A1 (de) * 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
CN104004739A (zh) * 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
CN101918025A (zh) 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP2506868B1 (de) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-fc-polypeptide und verfahren zu ihrer anwendung
US20120321607A1 (en) * 2010-01-28 2012-12-20 Novo Nordisk Health Care Ag Factor VII Fusion Polypeptides
SG188639A1 (en) 2010-10-06 2013-05-31 Medimmune Ltd Factor ii and fibrinogen for treatment of haemostatic disorders
CN103270046B (zh) * 2010-10-12 2016-05-11 费城儿童医院 治疗b型血友病的方法和组合物
EP2822577B1 (de) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
EP3564260B1 (de) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Faktor-viii-zusammensetzungen und verfahren zur herstellung und verwendung davon
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
WO2020051277A1 (en) * 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
WO2021030787A1 (en) * 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550011C2 (de) * 1975-11-07 1982-11-25 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines antihämophilen Mittels
DE2759053A1 (de) * 1977-12-30 1979-07-12 Uhlin Verfahren zum herstellen von genprodukten von plasmid-dns
EP0044343B1 (de) * 1980-01-28 1984-08-22 Baxter Travenol Laboratories, Inc. Prothrombin enthaltende therapeutische zusammensetzungen und verfahren zur herstellung enzymatisch aktiver blutgerinnungsfaktoren aus prothrombin enthaltenden blutfraktionen
US4381119A (en) * 1980-12-17 1983-04-26 Burroughs Corporation Multipart continuous form
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CA2406583A1 (en) * 2000-05-10 2001-11-15 Novo Nordisk A/S Pharmaceutical composition comprising a factor viia and a factor xiii
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
EP1446148A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit einem faktor-vii-polypeptid und epsilon-aminocapronsäure
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
EP1446150A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmazeutische zusammensetzung mit faktor-vii- polypeptiden und protein-c-inhibitoren
US20030118580A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and thrombomodulin polypeptides
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides

Also Published As

Publication number Publication date
PL365290A1 (en) 2004-12-27
CN1499981A (zh) 2004-05-26
IL156843A0 (en) 2004-02-08
KR20030078901A (ko) 2003-10-08
US20030199444A1 (en) 2003-10-23
HUP0303143A2 (hu) 2003-12-29
US20060276398A1 (en) 2006-12-07
HUP0303130A2 (hu) 2004-01-28
WO2002062376A1 (en) 2002-08-15
KR20030088430A (ko) 2003-11-19
RU2292909C2 (ru) 2007-02-10
ES2301624T3 (es) 2008-07-01
BR0207006A (pt) 2004-02-17
CA2436807A1 (en) 2002-08-15
BR0207007A (pt) 2004-02-17
RU2311923C2 (ru) 2007-12-10
EP1359935A1 (de) 2003-11-12
AU2002229510A1 (en) 2002-08-19
CN1592632A (zh) 2005-03-09
DE60225118D1 (de) 2008-04-03
US20080075711A1 (en) 2008-03-27
DE60225118T2 (de) 2009-03-05
WO2002062377A3 (en) 2003-03-27
WO2002062377A2 (en) 2002-08-15
IL156842A0 (en) 2004-02-08
US20060211621A1 (en) 2006-09-21
RU2003127018A (ru) 2005-03-10
JP2004517950A (ja) 2004-06-17
RU2003126911A (ru) 2005-02-27
JP2004517949A (ja) 2004-06-17
PL365293A1 (en) 2004-12-27
CA2437015A1 (en) 2002-08-15
EP1359936B1 (de) 2008-02-20
US20080076702A1 (en) 2008-03-27
EP1359936A2 (de) 2003-11-12

Similar Documents

Publication Publication Date Title
ATE386538T1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
HK1080517A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
DE50210317D1 (de) Peptid zur diagnose und therapie der alzheimer-demenz
TR200103469T2 (tr) Amiloidojenik hastalığının önlenmesi ve tedavisi
HUP0500060A2 (hu) Humán VII-es koagulációs faktor polipeptidek
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
TR200003347T2 (tr) Neisseria meningitidis'denBASB029 polinükleotidleri ve polipeptidler
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
BR0312889A (pt) Polipeptìdeo t20 peguilado
HUP0303167A2 (hu) IB-alfa vérlemezke glikoproteinnel képzett fúziós polipeptidek, továbbá eljárások alkalmazásukra
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2004056384A3 (en) Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix
WO2001051511A3 (de) Rekombinante herstellung von humanen histon 1-subtypen sowie deren verwendung für therapeutische zwecke
DE69434151D1 (de) Therapeutische inhaltsstoffe
EP1411964A4 (de) Die blutgerinnung modulierende peptide und ihre verwendungszwecke
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
SE9703287D0 (sv) Peptides
DE69707690D1 (de) Neue peptide und nootroper wirkstoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties